نتایج جستجو برای: tysabri
تعداد نتایج: 53 فیلتر نتایج به سال:
The Journal of Clinical Investigation http://www.jci.org Volume 118 Number 3 March 2008 825 The comeback kid: TYSABRI now FDA approved for Crohn disease The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to severely active Crohn disease (CD) who do not respond to, or do not tolerate, conventional therapies for CD and inh...
In recent years, two outstandingly effective drugs for the treatment of multiple sclerosis (MS) have appeared on the market: Tysabri® (Biogen Idec/Elan, 2008) and Gilenya® (Novartis, 2010). Tysabri (Natalizumab) is a humanized monoclonal antibody that binds to the cellular adhesion molecule alpha-4 integrin, which is used by lymphocytes to cross vascular walls and penetrate the blood-brain barr...
-
The treatment of relapsing-remitting multiple sclerosis (RRMS) has become more effective over the last decade with the advent of the currently available disease-modifying therapies (DMTs). Pivotal clinical studies differ in many characteristics, such that cross-comparisons of relative risk reductions are of limited value and can be misleading. Our objective was to compare the clinical efficacy ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید